Vertaling van "2008 annual report and includes " (Nederlands → Frans) :

The following non-exhaustive list relating to some cases reported in the 2008 Annual Report and includes information as of the 2008 fourth quarter:
Non exhaustive, la liste suivante passe en revue quelques-uns des cas cités dans le Rapport annuel 2008 et contient les informations disponibles au quatrième trimestre 2008.

In particular, as discussed in notes 9 and 10 of the 2008 Annual Report, Novartis regularly reviews long-lived intangible and tangible assets, including identifiable intangible assets and goodwill for impairment.
En particulier, comme l’expliquent les annexes 9 et 10 du Rapport annuel 2008, Novartis examine régulièrement les immobilisations corporelles et incorporelles à durée d’utilité indéterminée, notamment les immobilisations incorporelles identifiables et le goodwill susceptibles de subir une perte de valeur.

Further information, including assumptions used in determining the valuation of this investment as of December 31, 2008, is provided in the 2008 Annual Report and Form 20-F under “Critical Accounting Policies and Estimates”.
D’autres informations, comprenant les hypothèses utilisées pour déterminer la valeur de cet investissement au 31 décembre 2008, figurent dans le Rapport annuel 2008 et dans le formulaire 20 F sous «Critical Accounting Policies and Estimates» (Normes comptables et estimations importantes).

The following is a non-exhaustive list relating to some cases reported in the 2008 Annual Report and includes information as of the 2009 first half:
Non exhaustive, la liste suivante passe en revue quelques-uns des cas cités dans le Rapport annuel 2008 et contient les informations disponibles au premier semestre 2009.

The following is a non-exhaustive list relating to some cases reported in the 2008 Annual Report and includes information as of the first nine months in 2009:
Non exhaustive, la liste suivante passe en revue quelques-uns des cas cités dans le Rapport annuel 2008 et contient les informations disponibles au cours des neuf premiers mois de 2009.

In particular, as discussed in notes 8 and 9 of the 2008 Annual Report, Novartis regularly reviews long-lived intangible and tangible assets, including identifiable intangible assets and goodwill for impairment.
En particulier, comme l’expliquent les annexes 8 et 9 du Rapport annuel 2008, Novartis examine régulièrement les immobilisations corporelles et incorporelles à durée d’utilité indéterminée, notamment les immobilisations incorporelles identifiables et le goodwill susceptibles de subir une perte de valeur.

See note 20 in the Group’s Consolidated Financial Statements in the 2009 Annual Report for a summary of major legal proceedings. The following is a non-exhaustive list relating to some cases reported in the 2009 Annual Report and includes information as of the 2009 fourth quarter:
Pour un résumé des litiges majeurs, prière de consulter la note 20 des Comptes consolidés du Groupe figurant dans le rapport annuel 2009.La liste suivante, non exhaustive, passe en revue quelquesuns des cas cités dans le Rapport annuel 2009 et contient les informations disponibles au quatrième trimestre 2009.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

This report “The Federal Agency for Medicines and Health Products – 2008 in words and images. Annual Report 2008” was created under the coordination of the Communication Division of the FAMHP.
This report “The Federal Agency for Medicines and Health Products – 2008 in words and images. Annual Report 2008” was created under the coordination of the Communication Division of the FAMHP.

Both the SCF’s 2003 opinion and the advisory report recently published by the German Federal Institute for Risk Assessment (BfR, 2008) mention a number of observation cases and reported cases with acute adverse effects, including death, in people who consume energy drinks.
L’avis du SCF de 2003 ainsi que l’avis récemment émis par l’Institut fédéral allemand d’évaluation des risques (BfR, 2008) mentionnent un certain nombre de cas d’observation et de cas rapportés signalant des effets nocifs aigus, comprenant des décès, chez des sujets consommant des boissons énergisantes.